checkAd

     105  0 Kommentare Conference call on Interim Report

    GOTHENBURG, SWEDEN / ACCESSWIRE / October 6, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report July-September 2023. The presentation will be held in …

    GOTHENBURG, SWEDEN / ACCESSWIRE / October 6, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report July-September 2023. The presentation will be held in English.

    Time: Tuesday, October 24 at 2.00 pm. CET

    If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions.
    https://ir.financialhearings.com/xvivo-q3-2023

    If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. Via the teleconference you can ask questions verbally.
    https://conference.financialhearings.com/teleconference/?id=5002129

    Participants from XVIVO:
    Christoffer Rosenblad, CEO
    Kristoffer Nordström, CFO

    The press release for XVIVO's interim report July-September 2023 will be released on October 24, 2023 at 7:30 am. CET.

    Before the conference call, slides will be available at the company web page, https://www.xvivoperfusion.com/corporate/financial-presentations/earni ...

    October 6, 2023
    Gothenburg
    XVIVO Perfusion AB (publ)

    Lesen Sie auch

    For further information, please contact:

    Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com
    Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com

    About Us

    Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.

    Attachments

    Conference call on Interim Report

    SOURCE: XVIVO Perfusion AB



    View source version on accesswire.com:
    https://www.accesswire.com/790742/conference-call-on-interim-report


    The Xvivo Perfusion Stock at the time of publication of the news with a raise of +1,52 % to 268,0SEK on London stock exchange (05. Oktober 2023, 18:14 Uhr).


    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    Conference call on Interim Report GOTHENBURG, SWEDEN / ACCESSWIRE / October 6, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report July-September 2023. The presentation will be held in …